Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

PRTA Prothena Corp Public Ltd Co

Price (delayed)

$6.08

Market cap

$327.27M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.05

Enterprise value

-$80.46M

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating ...

Highlights
The company's gross profit has surged by 55% YoY and by 2.1% QoQ
Prothena's revenue has soared by 55% YoY and by 2.1% from the previous quarter
The quick ratio has declined by 32% year-on-year and by 11% since the previous quarter
The company's equity fell by 13% YoY and by 10% QoQ

Key stats

What are the main financial stats of PRTA
Market
Shares outstanding
53.83M
Market cap
$327.27M
Enterprise value
-$80.46M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.75
Price to sales (P/S)
2.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.58
Earnings
Revenue
$137.94M
Gross profit
$137.94M
Operating income
-$138.61M
Net income
-$110.27M
EBIT
-$115.86M
EBITDA
-$112.26M
Free cash flow
-$130.6M
Per share
EPS
-$2.05
EPS diluted
-$2.07
Free cash flow per share
-$2.43
Book value per share
$8.13
Revenue per share
$2.56
TBVPS
$9.2
Balance sheet
Total assets
$495.34M
Total liabilities
$57.66M
Debt
$10.2M
Equity
$437.68M
Working capital
$387.71M
Liquidity
Debt to equity
0.02
Current ratio
9
Quick ratio
8.62
Net debt/EBITDA
3.63
Margins
EBITDA margin
-81.4%
Gross margin
100%
Net margin
-79.9%
Operating margin
-100.5%
Efficiency
Return on assets
-19.3%
Return on equity
-21.6%
Return on invested capital
-280.7%
Return on capital employed
-25.9%
Return on sales
-84%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PRTA stock price

How has the Prothena stock price performed over time
Intraday
-1.62%
1 week
6.29%
1 month
32.75%
1 year
-70.38%
YTD
-56.1%
QTD
-50.87%

Financial performance

How have Prothena's revenue and profit performed over time
Revenue
$137.94M
Gross profit
$137.94M
Operating income
-$138.61M
Net income
-$110.27M
Gross margin
100%
Net margin
-79.9%
The operating margin has soared by 59% year-on-year and by 12% since the previous quarter
Prothena's net margin has soared by 59% YoY and by 12% from the previous quarter
The company's gross profit has surged by 55% YoY and by 2.1% QoQ
Prothena's revenue has soared by 55% YoY and by 2.1% from the previous quarter

Price vs fundamentals

How does PRTA's price correlate with its fundamentals

Growth

What is Prothena's growth rate over time

Valuation

What is Prothena stock price valuation
P/E
N/A
P/B
0.75
P/S
2.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.58
The company's EPS rose by 36% YoY and by 10% QoQ
PRTA's price to book (P/B) is 80% lower than its 5-year quarterly average of 3.8 and 56% lower than its last 4 quarters average of 1.7
The company's equity fell by 13% YoY and by 10% QoQ
PRTA's price to sales (P/S) is 99% lower than its 5-year quarterly average of 182.6 and 58% lower than its last 4 quarters average of 5.6
Prothena's revenue has soared by 55% YoY and by 2.1% from the previous quarter

Efficiency

How efficient is Prothena business performance
The ROIC has soared by 62% YoY and by 7% from the previous quarter
The company's return on sales has surged by 59% YoY and by 12% QoQ
The ROE has increased by 29% YoY and by 7% from the previous quarter
Prothena's return on assets has increased by 22% YoY and by 4.9% QoQ

Dividends

What is PRTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRTA.

Financial health

How did Prothena financials performed over time
The total liabilities has dropped by 52% year-on-year and by 4.2% since the previous quarter
The quick ratio has declined by 32% year-on-year and by 11% since the previous quarter
Prothena's debt is 98% less than its equity
Prothena's debt has decreased by 18% YoY and by 6% from the previous quarter
The company's equity fell by 13% YoY and by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.